It’s never a good sign when the government comes knocking at your door with a lot of questions. It’s usually a sign that something has gone wrong, and that appears to be the case for the Medicaid drug rebate program. The Health and Human Services Office of Inspector General recently announced it would conduct several reviews of the program, prompted by congressional concerns the program paid too much for EpiPens.
Both the Senate Finance Committee and the House Energy and Commerce Committee called for the reviews earlier in the year. The committees said the drug rebate program had misclassified EpiPen and other drugs as generics instead of brand-name drugs, resulting in lower rebate payments from the drug manufacturers.
I spoke with Ellyn Sternfield, a health-care attorney with Mintz Levin in Washington, who told me she expects the new reviews might not have much impact, since past reviews of the program have led to little change. Sternfield said the OIG reviewed drug misclassification in a July 2009 report and told the Centers for Medicare & Medicaid Services it had some concerns over classification accuracy.
Sternfield said it’ll be interesting to see if the new reports include details on what the CMS did, or didn’t, do on drug classification after the 2009 report.
The new OIG reviews will take a look at the CMS’s accuracy in classifying drugs in the rebate program, the Food and Drug Administration approval process for drugs paid for by Medicaid and how reasonable manufacturers are when setting drug prices for the rebate program.
The Medicaid drug rebate program helps offset the cost of Medicaid prescription drugs. Drug manufacturers pay a 23.1 percent rebate for brand-name products and a 13.1 percent rebate for generics.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)